Search
Artiva Biotherapeutics Inc
ARTVAdd to Watchlist
9.800USD
+0.440+4.70%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
476.16MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-23The current earnings forecast score of Artiva Biotherapeutics Inc is 8.67, ranking 73 out of 389 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 23.00 and a low of 10.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
35.800
Target Price
+282.48%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Artiva Biotherapeutics Inc
ARTV
6
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Artiva Biotherapeutics Inc's price target?
Analysts forecast that Artiva Biotherapeutics Inc's price target is USD 18.00, with the highest forecast at USD 23.00 and the lowest forecast at USD 10.00.
How have Artiva Biotherapeutics IncARTV's recent earnings per share performed?
The market expectation was USD -0.95, while Artiva Biotherapeutics IncARTV's earnings per share (EPS) for the previous quarter was USD -0.85. EPS for the next quarter is expected at USD -0.62.
What is the analyst rating for Artiva Biotherapeutics Inc?
Based on the ratings of Artiva Biotherapeutics Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
